-1 Receptors are expressed in the brain, and their activation has been shown to prevent neuronal death associated with glutamate toxicity. This study investigates the possible mechanism and effect of [2S-(2␣,6␣,11R*]-1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(2-propenyl)-2,6-methano-3-benzazocin-8-ol (SKF10047), a -1 receptor agonist, on endogenous glutamate release in the nerve terminals of rat cerebral cortex. Results show that SKF10047 inhibited the release of glutamate evoked by the K ϩ channel blocker 4-aminopyridine (4-AP), and the -1The effects of SKF10047 on the evoked glutamate release were prevented by the chelating extracellular Ca 2ϩ ions and the vesicular transporter inhibitor bafilomycin A1. However, the glutamate transporter inhibitor DL-threo--benzyl-oxyaspartate did not have any effect on the action of SKF10047. SKF10047 decreased the depolarization-induced increase in the cytosolic free Ca 2ϩ concentration ([Ca 2ϩ ] C ), but did not alter 4-AP-mediated depolarization. Furthermore, the effects of SKF10047 on evoked glutamate release were prevented by blocking the Ca v 2.2 (Ntype) and Ca v 2.1 (P/Q-type) channels, but not by blocking the ryanodine receptors or the mitochondrial Na ϩ /Ca 2ϩ exchange. In addition, conventional protein kinase C (PKC) inhibitors abolished the SKF10047 effect on 4-AP-evoked glutamate release. Western blot analyses showed that SKF10047 decreased the 4-AP-induced phosphorylation of PKC and PKC␣. These results show that -1 receptor activation inhibits glutamate release from rat cortical nerve terminals. This effect is linked to a decrease in [Ca 2ϩ ] C caused by Ca 2ϩ entry through presynaptic voltage-dependent Ca 2ϩ channels and the suppression of the PKC signaling cascade.